ES2952985T3 - Forma cristalina de hidrato de base libre de lorlatinib - Google Patents
Forma cristalina de hidrato de base libre de lorlatinib Download PDFInfo
- Publication number
- ES2952985T3 ES2952985T3 ES18795807T ES18795807T ES2952985T3 ES 2952985 T3 ES2952985 T3 ES 2952985T3 ES 18795807 T ES18795807 T ES 18795807T ES 18795807 T ES18795807 T ES 18795807T ES 2952985 T3 ES2952985 T3 ES 2952985T3
- Authority
- ES
- Spain
- Prior art keywords
- ppm
- free base
- crystalline form
- lorlatinib
- base hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952985T3 true ES2952985T3 (es) | 2023-11-07 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18795807T Active ES2952985T3 (es) | 2017-10-10 | 2018-10-04 | Forma cristalina de hidrato de base libre de lorlatinib |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063322A (zh) | 2015-07-31 | 2023-05-05 | 辉瑞公司 | 劳拉替尼游离碱的结晶形式 |
| JP2019510774A (ja) | 2016-04-08 | 2019-04-18 | ファイザー・インク | ロルラチニブマレイン酸塩の結晶質形態 |
| EP3784675A1 (en) * | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| KR20130105675A (ko) * | 2010-11-25 | 2013-09-25 | 라티오팜 게엠베하 | 아파티닙의 신규 염 및 다형 |
| JP6385273B6 (ja) * | 2011-06-08 | 2023-12-15 | バイオジェン・エムエイ・インコーポレイテッド | 高純度結晶性ジメチルフマラートの調製方法 |
| WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| CN116063322A (zh) | 2015-07-31 | 2023-05-05 | 辉瑞公司 | 劳拉替尼游离碱的结晶形式 |
| JP2019510774A (ja) | 2016-04-08 | 2019-04-18 | ファイザー・インク | ロルラチニブマレイン酸塩の結晶質形態 |
-
2018
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11299500B2 (en) | 2022-04-12 |
| EP3694863A1 (en) | 2020-08-19 |
| RU2020113141A3 (enExample) | 2021-11-12 |
| CA3077508A1 (en) | 2019-04-18 |
| JP2020536893A (ja) | 2020-12-17 |
| TWI775960B (zh) | 2022-09-01 |
| KR20200051781A (ko) | 2020-05-13 |
| SI3694863T1 (sl) | 2023-10-30 |
| US20200308191A1 (en) | 2020-10-01 |
| CN111201235A (zh) | 2020-05-26 |
| EP3694863B1 (en) | 2023-06-21 |
| PL3694863T3 (pl) | 2023-09-25 |
| RU2022109286A (ru) | 2022-05-06 |
| WO2019073347A1 (en) | 2019-04-18 |
| DK3694863T3 (da) | 2023-07-03 |
| KR102424621B1 (ko) | 2022-07-25 |
| CY1126141T1 (el) | 2023-11-15 |
| AU2018349259A1 (en) | 2020-04-09 |
| MX2020003373A (es) | 2020-10-12 |
| HUE062926T2 (hu) | 2023-12-28 |
| CN111201235B (zh) | 2023-02-10 |
| BR112020005989A2 (pt) | 2020-09-29 |
| FI3694863T3 (fi) | 2023-08-18 |
| SG11202002445SA (en) | 2020-04-29 |
| JP7153069B2 (ja) | 2022-10-13 |
| PT3694863T (pt) | 2023-08-23 |
| RU2020113141A (ru) | 2021-11-12 |
| TW201922753A (zh) | 2019-06-16 |
| ZA202001661B (en) | 2023-11-29 |
| CA3077508C (en) | 2023-02-14 |
| AU2018349259B2 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2842302T3 (es) | Forma cristalina de base libre de lorlatinib | |
| US11299500B2 (en) | Crystalline form of lorlatinib free base hydrate | |
| ES2819676T3 (es) | Formas cristalinas de maleato de lorlatinib | |
| WO2016079313A1 (en) | Crystalline forms of afatinib dimaleate | |
| RU2845218C2 (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| BR112020005989B1 (pt) | Forma cristalina de hidrato de base livre de lorlatinibe, composição e usos | |
| RU2852836C1 (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| HK40029499B (en) | Crystalline form of lorlatinib free base hydrate | |
| HK40029499A (en) | Crystalline form of lorlatinib free base hydrate |